BR112016017193A2 - Derivados de insulina, seus usos, e composição farmacêutica - Google Patents
Derivados de insulina, seus usos, e composição farmacêuticaInfo
- Publication number
- BR112016017193A2 BR112016017193A2 BR112016017193A BR112016017193A BR112016017193A2 BR 112016017193 A2 BR112016017193 A2 BR 112016017193A2 BR 112016017193 A BR112016017193 A BR 112016017193A BR 112016017193 A BR112016017193 A BR 112016017193A BR 112016017193 A2 BR112016017193 A2 BR 112016017193A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- pharmaceutical composition
- insulin derivatives
- insulin
- diabetes
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14157215 | 2014-02-28 | ||
| PCT/EP2015/053989 WO2015128403A2 (en) | 2014-02-28 | 2015-02-26 | Novel insulin derivatives and the medical uses hereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016017193A2 true BR112016017193A2 (pt) | 2017-10-03 |
Family
ID=50184804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016017193A BR112016017193A2 (pt) | 2014-02-28 | 2015-02-26 | Derivados de insulina, seus usos, e composição farmacêutica |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10040839B2 (enExample) |
| EP (1) | EP3110840B1 (enExample) |
| JP (1) | JP6580583B2 (enExample) |
| KR (1) | KR20160125988A (enExample) |
| CN (1) | CN106459171B (enExample) |
| AR (1) | AR099569A1 (enExample) |
| AU (1) | AU2015222135B2 (enExample) |
| BR (1) | BR112016017193A2 (enExample) |
| CA (1) | CA2941103A1 (enExample) |
| DK (1) | DK3110840T3 (enExample) |
| ES (1) | ES2831848T3 (enExample) |
| HR (1) | HRP20201732T1 (enExample) |
| HU (1) | HUE051355T2 (enExample) |
| IL (1) | IL246757B (enExample) |
| MX (1) | MX368387B (enExample) |
| PL (1) | PL3110840T3 (enExample) |
| PT (1) | PT3110840T (enExample) |
| RS (1) | RS61137B1 (enExample) |
| RU (1) | RU2684456C2 (enExample) |
| SA (1) | SA516371705B1 (enExample) |
| SI (1) | SI3110840T1 (enExample) |
| TW (1) | TWI686403B (enExample) |
| WO (1) | WO2015128403A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170028031A1 (en) * | 2014-03-07 | 2017-02-02 | Klavs Holger Jørgensen | Novel fast acting insulin preparations |
| CA2996455A1 (en) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| CA3294636A1 (en) * | 2016-11-21 | 2026-02-10 | Case Western Reserve University | Rapid-acting insulin analogues of enhanced stability |
| KR101909052B1 (ko) * | 2017-02-09 | 2018-10-17 | 강원대학교산학협력단 | 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물 |
| JP2020513019A (ja) * | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−Ｆｃコンジュゲート |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| PE20211264A1 (es) * | 2017-08-17 | 2021-07-15 | Novo Nordisk As | Analogos de insulina acilados novedosos y usos de estos |
| MA50414A (fr) | 2017-10-19 | 2020-08-26 | Mona E Buice | Composition à usage topique pour la cicatrisation améliorée des plaies ouvertes |
| TWI829687B (zh) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| SG11202106168VA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin analogs having reduced insulin receptor binding affinity |
| US12178879B2 (en) | 2019-02-13 | 2024-12-31 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivative and antibody-drug conjugate thereof |
| WO2020166600A1 (ja) | 2019-02-13 | 2020-08-20 | 大日本住友製薬株式会社 | システイン残基を有するヘミアスタリン誘導体 |
| ES3049784T3 (en) * | 2019-08-27 | 2025-12-18 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| FI4073097T3 (fi) | 2019-12-11 | 2024-08-13 | Novo Nordisk As | Uusia insuliinianalogeja ja niiden käyttötapoja |
| CN118772259A (zh) * | 2019-12-30 | 2024-10-15 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| KR20240013778A (ko) * | 2021-05-24 | 2024-01-30 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 신규한 아실화된 인슐린 유사체 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
| GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3864325A (en) | 1971-11-18 | 1975-02-04 | Nat Res Dev | (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| HUT56857A (en) * | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| JP3122128B2 (ja) * | 1989-12-21 | 2001-01-09 | ノボ ノルディスク アクティーゼルスカブ | ペプチド製剤 |
| SI0792290T1 (en) | 1993-09-17 | 2001-12-31 | Novo Nordisk As | Acylated insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6703017B1 (en) * | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| CA2215694A1 (en) | 1995-03-17 | 1996-09-26 | Novo Nordisk A/S | Insulin derivatives |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US5898067A (en) | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| IL131796A0 (en) | 1997-03-20 | 2001-03-19 | Novo Nordisk As | Zinc free insulin crystals for use in pulmonary compositions |
| ES2202899T3 (es) | 1997-10-24 | 2004-04-01 | Novo Nordisk A/S | Agregados de derivados de la insulina humana. |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| SV1998000125A (es) | 1997-10-24 | 1999-05-24 | Lilly Co Eli | Composiciones de insulina insoluble ref. x-11232 |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| EP1044016B1 (en) | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilised insulin compositions |
| EP1086130A1 (en) | 1998-06-12 | 2001-03-28 | Kings College London | Insulin analogue |
| AU5454200A (en) | 1999-06-29 | 2001-01-31 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| WO2001093837A2 (en) | 2000-06-08 | 2001-12-13 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| WO2003048195A2 (en) | 2001-12-02 | 2003-06-12 | Novo Nordisk A/S | Glucose dependant release of insulin from glucose sensing insulin derivatives |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| AU2003208316A1 (en) | 2002-03-13 | 2003-09-22 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| US20060217290A1 (en) | 2003-04-29 | 2006-09-28 | Kohn Wayne D | Insulin analogs having protracted time action |
| EP1644411A2 (en) | 2003-07-11 | 2006-04-12 | Novo Nordisk A/S | Stabilised insulin compositions |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| CN102552917A (zh) | 2003-08-13 | 2012-07-11 | 比奥孔有限公司 | 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂 |
| EP1687428A1 (en) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー／エス | 単鎖インシュリン |
| WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
| MX2007000883A (es) | 2004-07-19 | 2007-04-02 | Biocon Ltd | Conjugados de insulina-oligomero, formulaciones y usos de los mismos. |
| JP5410020B2 (ja) | 2005-02-02 | 2014-02-05 | ノヴォ ノルディスク アー／エス | インスリン誘導体 |
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| DE602007009496D1 (de) | 2006-02-27 | 2010-11-11 | Novo Nordisk As | Insulinderivate |
| EP2015770B1 (en) | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| US8796205B2 (en) | 2006-05-09 | 2014-08-05 | Novo Nordisk A/S | Insulin derivative |
| WO2008013938A2 (en) | 2006-07-27 | 2008-01-31 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
| EP2049149B1 (en) | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylated extended insulins |
| EP2404934A1 (en) * | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Protease resistant insulin analogues |
| WO2008145721A2 (en) | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009015456A1 (en) | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
| KR20100053561A (ko) | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| WO2009060071A1 (en) | 2007-11-08 | 2009-05-14 | Novo Nordisk A/S | Insulin derivative |
| ES2612736T3 (es) | 2007-11-16 | 2017-05-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| ES2618073T3 (es) | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| MX2010009850A (es) * | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| CN106317164A (zh) | 2008-09-12 | 2017-01-11 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| CA2738615A1 (en) | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| PT2459171T (pt) * | 2009-07-31 | 2017-08-16 | Sanofi Aventis Deutschland | Composição de insulina de atuação longa |
| EP2569002B1 (en) | 2010-05-10 | 2016-10-26 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| EP2585484A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| CN103415300B (zh) | 2010-07-20 | 2018-02-23 | 诺沃—诺迪斯克有限公司 | N‑末端修饰的fgf21化合物 |
| CN103596584B (zh) * | 2011-06-15 | 2016-12-14 | 诺沃—诺迪斯克有限公司 | 多取代的胰岛素 |
| AU2012328407A1 (en) | 2011-10-27 | 2014-05-22 | Case Western Reserve University | Ultra-concentrated rapid-acting insulin analogue formulations |
-
2015
- 2015-02-25 AR ARP150100559A patent/AR099569A1/es unknown
- 2015-02-26 SI SI201531416T patent/SI3110840T1/sl unknown
- 2015-02-26 MX MX2016010899A patent/MX368387B/es active IP Right Grant
- 2015-02-26 WO PCT/EP2015/053989 patent/WO2015128403A2/en not_active Ceased
- 2015-02-26 EP EP15707102.8A patent/EP3110840B1/en active Active
- 2015-02-26 AU AU2015222135A patent/AU2015222135B2/en not_active Ceased
- 2015-02-26 RS RS20201399A patent/RS61137B1/sr unknown
- 2015-02-26 PT PT157071028T patent/PT3110840T/pt unknown
- 2015-02-26 TW TW104106145A patent/TWI686403B/zh not_active IP Right Cessation
- 2015-02-26 ES ES15707102T patent/ES2831848T3/es active Active
- 2015-02-26 BR BR112016017193A patent/BR112016017193A2/pt not_active Application Discontinuation
- 2015-02-26 JP JP2016554498A patent/JP6580583B2/ja active Active
- 2015-02-26 US US15/121,206 patent/US10040839B2/en active Active
- 2015-02-26 RU RU2016135543A patent/RU2684456C2/ru active
- 2015-02-26 KR KR1020167024826A patent/KR20160125988A/ko not_active Withdrawn
- 2015-02-26 CN CN201580010746.3A patent/CN106459171B/zh active Active
- 2015-02-26 HR HRP20201732TT patent/HRP20201732T1/hr unknown
- 2015-02-26 DK DK15707102.8T patent/DK3110840T3/da active
- 2015-02-26 CA CA2941103A patent/CA2941103A1/en not_active Withdrawn
- 2015-02-26 PL PL15707102T patent/PL3110840T3/pl unknown
- 2015-02-26 HU HUE15707102A patent/HUE051355T2/hu unknown
-
2016
- 2016-07-13 IL IL246757A patent/IL246757B/en active IP Right Grant
- 2016-08-21 SA SA516371705A patent/SA516371705B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016135543A3 (enExample) | 2018-08-30 |
| US10040839B2 (en) | 2018-08-07 |
| IL246757B (en) | 2020-04-30 |
| JP6580583B2 (ja) | 2019-09-25 |
| US20170008945A1 (en) | 2017-01-12 |
| PT3110840T (pt) | 2020-11-26 |
| HUE051355T2 (hu) | 2021-03-01 |
| RU2016135543A (ru) | 2018-03-30 |
| AR099569A1 (es) | 2016-08-03 |
| CA2941103A1 (en) | 2015-09-03 |
| SI3110840T1 (sl) | 2020-12-31 |
| WO2015128403A2 (en) | 2015-09-03 |
| WO2015128403A3 (en) | 2015-12-10 |
| RU2684456C2 (ru) | 2019-04-09 |
| TWI686403B (zh) | 2020-03-01 |
| AU2015222135B2 (en) | 2018-12-20 |
| IL246757A0 (en) | 2016-08-31 |
| CN106459171A (zh) | 2017-02-22 |
| AU2015222135A1 (en) | 2016-07-28 |
| EP3110840A2 (en) | 2017-01-04 |
| TW201620930A (zh) | 2016-06-16 |
| HRP20201732T1 (hr) | 2020-12-25 |
| MX368387B (es) | 2019-10-01 |
| ES2831848T3 (es) | 2021-06-09 |
| DK3110840T3 (da) | 2020-11-02 |
| EP3110840B1 (en) | 2020-10-21 |
| MX2016010899A (es) | 2016-11-18 |
| CN106459171B (zh) | 2020-12-15 |
| PL3110840T3 (pl) | 2021-04-06 |
| RS61137B1 (sr) | 2020-12-31 |
| KR20160125988A (ko) | 2016-11-01 |
| SA516371705B1 (ar) | 2019-10-08 |
| JP2017508741A (ja) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016017193A2 (pt) | Derivados de insulina, seus usos, e composição farmacêutica | |
| BR112018002416A2 (pt) | derivados de insulina e seus usos médicos | |
| CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
| BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201591371A1 (ru) | Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock | |
| IN2014MN02056A (enExample) | ||
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| CL2020000310A1 (es) | Análogos de insulina acilados novedosos y usos de estos. | |
| MX375982B (es) | Compuesto de insulina acilada. | |
| EP3566702A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE | |
| EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл | |
| BR112016027383A8 (pt) | derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| CO2022007273A2 (es) | Análogos de insulina novedosos y usos de estos | |
| BR112017001803A2 (pt) | aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| BR112016029619A8 (pt) | Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| BR112018008076A2 (pt) | derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos | |
| BR112017003881A2 (pt) | derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak | |
| BR112018007269A2 (pt) | compostos de oxa-diazaespiro tendo atividade contra dor | |
| BR112017025270A2 (pt) | composto, composição farmacêutica, e, medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B10A | Cessation: cessation confirmed | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |